a6105a18-de2b-470c-bbb1-8c1188c57e22
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.500
- TGF_BETA_SIGNALING+0.500
- UV_RESPONSE_DN+0.400
- APICAL_JUNCTION+0.300
- COAGULATION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- MYOGENESIS+0.300
- PROTEIN_SECRETION+0.300
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.500
- MYC_TARGETS_V2-0.400
- INTERFERON_ALPHA_RESPONSE-0.300
- BILE_ACID_METABOLISM-0.200
- DNA_REPAIR-0.200
- E2F_TARGETS-0.200
- FATTY_ACID_METABOLISM-0.200
- G2M_CHECKPOINT-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- MTORC1_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR9879273 | — | cohortMD2 | 0.885 |
| 2 | TCGA-A8-A08Z-01A-21R-A00Z-07 | — | A | 0.881 |
| 3 | SRR25043621 | — | — | 0.871 |
| 4 | TCGA-EW-A2FR-01A-11R-A21T-07 | — | C | 0.862 |
| 5 | TCGA-44-6774-01A-21R-1858-07 | — | cohortA1 | 0.860 |
| 6 | TCGA-77-8008-01A-21R-2187-07 | — | cohortSQ1 | 0.851 |
| 7 | TCGA-BH-A1EO-01A-11R-A137-07 | — | A | 0.850 |
| 8 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.848 |
| 9 | 22620634-aa34-4cb5-a37f-5a7b0c47cd0e | — | — | 0.843 |
| 10 | TCGA-CR-6474-01A-11R-1873-07 | — | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |